Samenvatting: TEVIMBRA goedgekeurd in de VS voor eerstelijns behandeling van gevorderd oesofageaal plaveiselcelcarcinoom in combinatie met chemotherapie
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Source: Businesswire
FDA Approval Announcement: BeiGene, Ltd. has received FDA approval for TEVIMBRA® (tislelizumab-jsgr) in combination with platinum-based chemotherapy for the first-line treatment of adults with non-resectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (≥1).
Company Name Change: The company plans to change its name from BeiGene, Ltd. to BeOne Medicines Ltd.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
